Brokerages Set HTG Molecular Diagnostics Inc (NASDAQ:HTGM) Target Price at $2.17

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) has been given an average recommendation of “Buy” by the six ratings firms that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $1.23.

HTGM has been the topic of several research analyst reports. ValuEngine raised HTG Molecular Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, March 3rd. HC Wainwright cut their price target on HTG Molecular Diagnostics from $2.00 to $1.50 and set a “buy” rating on the stock in a research report on Thursday. Craig Hallum lowered HTG Molecular Diagnostics from a “buy” rating to a “hold” rating and set a $0.70 price target on the stock. in a research report on Thursday. Finally, Zacks Investment Research raised HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 17th.

Hedge funds have recently made changes to their positions in the business. Cowen Prime Services LLC grew its stake in shares of HTG Molecular Diagnostics by 2,037.9% in the 4th quarter. Cowen Prime Services LLC now owns 2,137,900 shares of the medical research company’s stock valued at $1,501,000 after purchasing an additional 2,037,900 shares during the last quarter. Perkins Capital Management Inc. grew its stake in shares of HTG Molecular Diagnostics by 7.4% in the 4th quarter. Perkins Capital Management Inc. now owns 2,527,000 shares of the medical research company’s stock valued at $1,774,000 after purchasing an additional 173,847 shares during the last quarter. HighMark Wealth Management LLC purchased a new position in shares of HTG Molecular Diagnostics in the 4th quarter valued at approximately $134,000. Finally, Geode Capital Management LLC grew its stake in shares of HTG Molecular Diagnostics by 58.3% in the 4th quarter. Geode Capital Management LLC now owns 385,645 shares of the medical research company’s stock valued at $270,000 after purchasing an additional 142,012 shares during the last quarter. Institutional investors own 32.38% of the company’s stock.

HTGM traded down $0.01 during trading on Monday, hitting $0.33. 4,100,098 shares of the stock were exchanged, compared to its average volume of 840,920. The firm has a market capitalization of $20.32 million, a P/E ratio of -0.57 and a beta of 1.33. HTG Molecular Diagnostics has a 1-year low of $0.30 and a 1-year high of $3.24. The stock has a fifty day moving average price of $0.49 and a two-hundred day moving average price of $0.67. The company has a quick ratio of 5.07, a current ratio of 5.21 and a debt-to-equity ratio of 0.34.

HTG Molecular Diagnostics (NASDAQ:HTGM) last released its quarterly earnings results on Wednesday, March 25th. The medical research company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.08. HTG Molecular Diagnostics had a negative return on equity of 88.60% and a negative net margin of 76.97%. Analysts predict that HTG Molecular Diagnostics will post -0.54 EPS for the current year.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing.

Featured Story: Moving Average – How it Helps Investors in Stock Selection

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.